Table 3

Positivity for gonorrhoea, Chlamydia, syphilis and HIV among men who have sex with men attending a sexual health centre in Melbourne, 2011–2018, stratified by men who have sex with men only (MSMO) and men who have sex with men and women (MSMW)

HIV/STIMen who have sex with men only (N=12 795)Men who have sex with men and women (N=1979)P value
No of men tested, NNo of positive, nPositivity, % (95% CI)No of men tested, NNo of positive, nPositivity, % (95% CI)
Gonorrhoea
 Oropharyngeal11 8106825.8 (5.4 to 6.2)1711684.0 (3.1 to 5.0)0.002
 Urethral*11 6993903.3 (3.0 to 3.7)1885522.8 (2.1 to 3.6)0.192
 Anorectal11 0807456.7 (6.3 to 7.2)1404584.1 (3.2 to 5.3)<0.001
 Any anatomical site†11 951132111.1 (10.5 to 11.6)18291407.7 (6.5 to 9.0)<0.001
Chlamydia
 Urethral11 6994103.5 (3.2 to 3.9)1885733.9 (3.0 to 4.8)0.423
 Anorectal11 0439899.0 (8.4 to 9.5)1404835.9 (4.7 to 7.3)<0.001
 Any anatomical site†11 891127210.7 (10.1 to 11.3)19071417.4 (6.3 to 8.7)<0.001
 Syphilis11 3177977.0 (6.6 to 7.5)1773814.6 (3.6 to 5.6)<0.001
HIV
 New diagnosis‡11 1022622.4 (2.1 to 2.7)1774100.6 (0.3 to 1.0)<0.001
 Previous diagnosis12 7953162.5 (2.2 to 2.8)197970.4 (0.1 to 0.7)<0.001
  • *Before 2015, urethral gonorrhoea testing was only performed among symptomatic MSM with urethral symptoms or self-reported as contact of infection. The number of people tested corresponds to the number of people tested for urethral chlamydia.

  • †Any anatomical site for gonorrhoea includes urethral, anorectal and oropharyngeal; while any site for chlamydia includes urethral and anorectal.

  • ‡Only including HIV cases diagnosed on the day of the first visit.

  • CI, confidence interval ; STI, sexually transmitted infection.